Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02355028 · ClinicalTrials.gov registry record · Phase 2
LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration
A Phase 2 study, sponsored by Alcon, a Novartis Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT02355028 is a Phase 2 study that has completed, run by Alcon, a Novartis Company. The registered enrollment target is 136 participants.
The verdict
NCT02355028, a Phase 2 study, has completed, sponsored by Alcon, a Novartis Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) therapy (Lucentis®) for recurrence of active choroidal neovascularization (CNV).
Interventions
- DRUG LHA510 ophthalmic suspension
- DRUG LHA510 vehicle
- DRUG Ranibizumab ophthalmic solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2015-03-03 |
| Est. Completion | 2016-10-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02355028
The ClinicalTrials.gov registry entry for NCT02355028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alcon, a Novartis Company, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which LHA510 ophthalmic suspension is the first listed.
NCT02355028 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02355028 about?
NCT02355028 is a clinical study titled "LHA510 Proof-of-Concept Study as a Maintenance Therapy for Patients With Wet Age-Related Macular Degeneration". The purpose of this study is to evaluate the efficacy of 84 successive days of topically administered LHA510 compared to vehicle in reducing the number of patients requiring intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) therapy (Lucentis®) for recurrence of active choroidal neova...
What is the current status of trial NCT02355028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2015-03-03. Estimated completion is 2016-10-18.
What interventions are being tested in trial NCT02355028?
The interventions under investigation include: LHA510 ophthalmic suspension (DRUG), LHA510 vehicle (DRUG), Ranibizumab ophthalmic solution (DRUG).
Who is sponsoring clinical trial NCT02355028?
This trial is sponsored by Alcon, a Novartis Company, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.